Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Besivance in Bacterial Conjunctivitis
NCT00347932Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jun 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in bacterial conjunctivitis (BC) comparing ISV-403 with Vehicle (2 arms). Primary endpoints: Clinical Resolution of Baseline Bacterial Conjunctivitis at Day 5 and Microbial Eradication of Baseline Bacterial Infection at Day 5. Started Jun 2006; status: completed.
02
Drugs
besifloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT00347932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00347932.